Drugs / Lemzoparlimab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04895410 | Jan → Jun 2022 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04912063 | Jun 2021 → May 2023 | acute myeloid leukemia, myelodysplastic syndrome | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03934814 | Apr 2019 → Jan 2023 | cancer, lymphoma | I-Mab Biopharma US Limited | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05148533 | Dec 2021 → Feb 2023 | neoplasm | TJ Biopharma Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04202003 | Mar 2020 → Dec 2023 | acute myeloid leukemia, myelodysplastic syndrome | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05709093 | Mar 2023 → Apr 2024 | myelodysplastic syndrome | TJ Biopharma Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lemzoparlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04895410 ↗ |
| Known as | TJ011133 | “TJ011133 (30 mg/kg, 45 mg/kg, QW) in combination with toripalimab injection (240 mg, Q3W).” NCT05148533 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650520 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion” NCT04895410 ↗ |